Lactoferrin supplementation for taste and smell abnormalities among patients receiving cancer chemotherapy.

ABSTRACT:

Purpose

Taste and smell abnormalities (TSA) are common in patients receiving chemotherapy and may lead to altered nutritional intake, treatment withdrawal, and impaired quality of life. Lipid peroxidation in the oral cavity is one cause of TSA. Lactoferrin (LFN), an iron-binding salivary protein, reduces production of lipid oxidation byproducts and has been shown to reduce perception of unpleasant flavors. To assess the feasibility of LFN as a treatment for TSA, we conducted pilot investigations among patients with cancer who self-reported TSA following onset of chemotherapy. The primary objective was to assess change in subjective taste and smell perception from baseline to completion of 30 days of LFN supplementation.

Methods

Patients were treated with 750 mg LFN daily for

SUBMITTER: Lesser GJ 

PROVIDER: S-EPMC9153138 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature